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CIC-DUX4 is a transcription factor fusion that defines certain undifferentiated round cell sarcomas with high metastatic propensity and poor clinical outcomes.
The molecular targets regulated by the CIC-DUX4 oncoprotein that promote this aggressive malignancy remain largely unknown. We show that increased expression of ETV4 and CCNE1 occurs via neo-morphic, direct effects of CIC-DUX4 and drives tumor metastasis and survival, respectively. We demonstrate a molecular dependence on the CCNE-CDK2 cell cycle complex that renders CIC-DUX4 tumors sensitive to inhibition of the CCNE-CDK2 complex, highlighting a therapeutic strategy for CIC-DUX4 tumors. Our findings highlight a paradigm of functional diversification of transcriptional repertoires controlled by a geneticallyaberrant transcriptional regulator, with therapeutic implications.
Introduction. The biological regulation of transcription factors and repressor
proteins is an essential mechanism to maintain cellular homeostasis, and is often dysregulated in human cancer 1 . Indeed, chromosomal rearrangements involving transcriptional regulatory genes that lead to transcriptional dysregulation are present in many cancers, including ~30% of all soft-tissue sarcomas 2 . The majority of these oncogenic fusions involve transcription factors or regulators that are not readily "druggable" in a direct pharmacologic manner, and thus have proven difficult to therapeutically target in the clinic. A prime example is the CIC-CIC-DUX4 tumors show ETV4 upregulation by immunohistochemistry (IHC), which distinguishes them from other small round blue cell sarcomas 8 . We and others have demonstrated a pro-metastatic function for ETV4 overexpression in tumors with inactivation of wild-type (WT) CIC 9, 10 . The functional role of ETV4 in CIC-DUX-positive tumors is unknown.
Beyond ETV4, the identity and function of other CIC target genes are less welldefined. Intriguingly, recent studies showed increased expression of cell-cycle regulatory genes in CIC-rearranged sarcomas, although the functional relevance of this observation for oncogenesis and cancer growth in this context is unclear 6, 7 .
Here, we develop a range of in vitro and in vivo cancer model systems to define the mechanism by which CIC-DUX4 co-opts transcriptional pathways that native CIC controls to promote hallmark features of malignancy, including tumor cell survival, growth, and metastasis.
Results and Discussion.
We recently reported that inactivation of native CIC de-represses an ETV4-MMP24 mediated pro-metastatic circuit 9 . Since ETV4 is a direct transcriptional target of CIC-DUX4 (Fig. S1A ) 6, 7 , we hypothesized that the high metastatic rate observed in patients harboring CIC-DUX4 fusions was dependent on ETV4 expression. To explore this hypothesis, we developed an orthotopic soft-tissue metastasis model that utilizes luciferase-based imaging to track tumor dissemination in vivo (Fig. 1A) .
This system produces rapid pulmonary metastases that accurately recapitulates metastatic tumor dissemination in human patients 3 . Using this in vivo system, we engineered NIH-3T3 mouse fibroblasts that offer the advantage of a geneticallycontrolled system (as with the study of other oncoproteins), to express the CIC-DUX4 fusion oncoprotein [11] [12] [13] . We observed rapid primary tumor formation at the site of implantation in 100% of the injected mice (Fig. 1B) . Genetic silencing of ETV4 decreased expression of its established target MMP24 9 ( Fig. 1C) , and
We next investigated transcriptional targets and programs that could regulate other key aspects of tumor biology beyond metastasis, including tumor cell proliferation and growth. Prior studies suggested that the CIC-DUX4 fusion can regulate cellcycle gene expression 6, 7 . We established that ectopic expression of CIC-DUX4
in NIH-3T3 cells increased tumor growth in vitro and in vivo through enhanced cellcycle progression (Fig. S1B-S1E ). The CIC-DUX4 fusion increased the number of cells progressing through S-phase, as reflected by an increased G2/M fraction compared to control ( Fig. S1F-G ). This CIC-DUX4 mediated cell-cycle progression was reversed upon 5-fluorouracil (5-FU) treatment ( Fig. S1F-G ). Since 5-FU induces a G1/S arrest, we hypothesized that the CIC-DUX4 fusion regulates late G1 and S phase-promoting genes. In order to identify these CIC-DUX4 regulated cell-cycle genes, we leveraged a publicly available microarray-based dataset (GSE60740) to perform a comparative transcriptional analysis between CIC-DUX4
replete (IB120 EV cell line) and two independent CIC-DUX4 knockdown (KD) patient-derived cell lines (IB120 shCIC-DUX4a and IB120 shCIC-DUX4b) 14 . Upon CIC-DUX4 KD, we observed 409 and 205 down-regulated genes (logFC < -2, FDR <0.05) in IB120 shCICDUX4a and IB120 shCIC-DUX4b, respectively ( Fig. 2A ).
There were 165 shared genes between the two shCIC-DUX4 datasets. Functional clustering of the 165 putative CIC-DUX4 target genes revealed enrichment for genes that regulate DNA replication and cell-cycle machinery (Fig. 2B) . By comparing the differential expression of these 165 genes between 14 CIC-DUX4
and 6 EWS-NFATC2 patient-derived tumors (GSE60740), we observed a significant increase in expression of multiple cell-cycle regulatory genes in CIC-DUX4 tumors (Fig. 2C ). Our findings extend recent studies 6, 7 , and indicate that targeting the cell-cycle in CIC-DUX4 tumors is a potential therapeutic approach.
In order to identify direct transcriptional targets of the CIC-DUX4 fusion, we first surveyed the promoters (within -2kb and +150bp of the transcriptional start site) of all 165 putative response genes for the highly conserved CIC binding motif
. Using this systematic approach, we identified 37 genes, including the known CIC target genes ETV1/4/5 and multiple regulators of the cellcycle (Table S1 ). Since ectopic expression of CIC-DUX4 promoted S-phase progression ( Fig. S1F-G) , we focused on genes that directly regulated the G1/S transition. Of these genes, CCNE1 expression was consistently upregulated in CIC-DUX4 tumors (Fig. 2C) . We therefore investigated whether CIC-DUX4 transcriptionally controls CCNE1 expression. To explore this hypothesis, we first localized two tandem CIC-binding motifs within 1kb of the CCNE1 transcriptional start site (Fig. 3A) . We next performed chromatin immunoprecipitation PCR (ChIP-PCR) analysis, which revealed CCNE1 promoter occupancy by the CIC-DUX4 fusion ( Fig. 3B-C) . Additionally, a luciferase-based reporter assay demonstrated enhanced promoter activity by the ectopic expression of CIC-DUX4 compared to CIC wild-type and empty-vector (EV) control (Fig. 3D ). These data show that CCNE1 is a direct transcriptional target that is upregulated by CIC-DUX4.
To explore the functional role of CCNE1 in CIC-DUX4-expressing tumors, we 15 . These findings suggest that pharmacologic inhibition of the CCNE-CDK2 complex is a potential therapeutic strategy in CIC-DUX4 expressing tumors.
There are few patient-derived models of CIC-DUX4-positive tumors.
Nevertheless, in order to increase the clinical relevance of our findings we obtained rare, established patient-derived CIC-DUX4 expressing cells (NCC-CDS1-X1 and NCC-CDS-X3) 18 to test the functional impact of ETV4 KD and CDK2 inhibition.
Consistent with the findings arising from our isogenic NIH-3T3 system, we found that genetic silencing of ETV4 decreased invasiveness, but did not impact tumor growth ( Fig. S3A-B) . Additionally, we found that CIC-DUX4 expressing cells were exquisitely sensitive to nanomolar (nM) concentrations of two established, independent CDK2 inhibitors, dinaciclib and SNS-032 15, 19 (Fig. 4D, S3C -E). The effects on tumor viability were largely mediated through apoptotic cell death as measured by caspase activity and PARP cleavage, again indicating that CIC-DUX4 tumors are dependent on the CCNE-CDK2 complex for survival ( Fig. 4E- G). To further demonstrate the therapeutic specificity of targeting CDK2, we used the clinical CDK4/6 inhibitor palbociclib that has no substantial activity against CDK2, and found no impact on tumor growth or apoptosis in NCC-CDS-X1 cells ( converge on, and activate CDK2, which our pharmacologic and genetics studies described above indicate is required for CIC-DUX4-expressing tumor survival 20 .
Our data suggest that in patient-derived NCC-CDS-X1 cells CCNE2 can compensate for CCNE1 loss. Consistent with this finding, we observed significant (~100-fold) upregulation of CCNE2 mRNA upon genetic silencing of CCNE1 ( Collectively, our data suggest that human CIC-DUX4-expressing cells have a specific dependence on the CCNE-CDK2 cell-cycle regulatory complex. Our mechanistic dissection of CIC-DUX4 tumors reveals a unique molecular and therapeutic dependence on the CCNE-CDK2 cell cycle complex. Our data show that this dependence can be exploited with clinical CDK2 inhibitors that limit tumor growth through apoptotic induction in a tumor type with few effective therapies.
The CIC-DUX4 fusion oncoprotein is a relatively understudied molecular entity that characterizes a rare, albeit lethal subset of undifferentiated round cell sarcomas.
We undertook a mechanistic dissection of the molecular function of the CIC-DUX4 fusion oncoprotein and report unique dependencies on specific transcriptional targets of the fusion oncoprotein that promote either tumor growth or metastasis.
We reveal that ETV4 is a conserved target gene that enhances the metastatic capacity of CIC-DUX4 tumors, without significantly impacting tumor growth. These findings extend previous data that demonstrate a pro-metastatic role for ETV4 in certain human cancer s 9, 21 . Targeting an ETV4-mediated transcriptional program downstream of CIC-DUX4 can potentially limit tumor dissemination.
Further analysis of CIC-DUX4-bearing tumors coupled with our functional studies also identified a dependence on specific cell-cycle machinery to enhance tumor growth, but not invasive capacity. We reveal that the CCNE-CDK2 complex is a molecular target of the CIC-DUX4 oncoprotein that controls tumor growth and FBS, 100 IU/ml penicillin and 100ug/ml streptomycin in a 5% CO2 atmosphere.
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